期刊文献+

我院门诊及住院处方审核中重复用药模块规则的精细化设置 被引量:7

Refined Setting of Rules for Repeated Medication Modules in the Prescription Review of Outpatient and Inpatient
下载PDF
导出
摘要 目的:通过精细化设置处方审核规则,提高处方审核的有效性,促进临床合理用药。方法:总结门诊及住院处方审核系统的重复用药警示中存在的问题,对问题的合理性进行分析,并对不合理警示进行规则修改。结果:自2020年7月中旬精细化设置重复用药规则后,药师干预问题处方成功率显著提高,重复用药红灯警告百分率和门诊处方不合理率逐步下降。结论:我院对处方审核系统进行精细化规则设置有利于提高临床用药合理性,提高临床医生对处方审核的接受程度和药师的工作效率。 Objective:To improve the effectiveness and rationality of prescription review through refinded rules setting,and to promote the rational use of drugs in clinical.Methods:The problems of repeated medication warnings by the system were summarized,the rationality of the problems were analyzed,and the rules of unreasonable warnings were modified.Results:Since the establishment of refined rules in mid-July 2020,the success rate of pharmacist intervention in problem prescriptions was increased,the red light warning rate of repeated medications and the rate of unreasonable outpatient prescriptions was gradually decreased.Conclusion:The setting of rules for the prescription review system by pharmacists in prescription review center has improved the rationality of medication usage,has improved the acceptance of prescription review by clinicians and has increased the efficiency of pharmacists’work.
作者 曾露 郭敏 刘金玉 刘秀兰 李为 李娟 刘东 Zeng Lu;Guo Min;Liu Jinyu;Liu Xiulan;Li Wei;Li Juan;Liu Dong(Department of Pharmacy,Tongji Hospital,Tongji Medical College of Huazhong University of Science,Wuhan 430030,China)
出处 《药物流行病学杂志》 CAS 2021年第6期388-392,共5页 Chinese Journal of Pharmacoepidemiology
基金 国家重点研发计划项目(编号:2020YEC2009000、2020YEC2009001)。
关键词 处方审核 重复用药 用药规则 精细化设置 合理用药 Prescription review Repeated medication Medication rule Refined setting Rational drug use
  • 相关文献

参考文献10

二级参考文献99

  • 1Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults : expert opinion, 2005. Epilepsy Behav, 2005, 7 Suppl 1 : S1-64.
  • 2French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I. Treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology, 2004, 62: 1252-1260.
  • 3Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening seizures. Epilepsia, 1998, 39 : 5-17.
  • 4Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med, 2000, 342: 314-319.
  • 5Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet, 2007, 369 : 1016-1026.
  • 6Beghi E, Gatti G, Tonini C, et al. Adjunctive therapy versus ahernative monotherapy in patients with partial epilepsy failing on a single drug: a muhicentre, randomized, pragmatic controlled trial. Epilepsy Res, 2003, 57: 1-13.
  • 7Kwan P, Brodie MJ. Epilepsy after the first drug fails : substitution or add-on? Seizure, 2000, 9: 464468.
  • 8Hauser WA. Seizure disorders: the changes with age. Epilepsia, 1992, 33 Suppl 4: $6-14.
  • 9Wallace H, Shorvon S, Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet, 1998, 352: 1970-1973.
  • 10Faught E. Monotherapy in adults and elderly persons. Neurology, 2007, 69 (24 Suppl 3 ) : $3-$9.

共引文献467

同被引文献102

引证文献7

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部